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Abstract
Background: Prostate biopsy parameters are commonly used to attribute cancer risk. A
targeted approach to lesions found on imaging may have an impact on the risk
attribution given to a man.
Objective: To evaluate whether, based on computer simulation, targeting of lesions
during biopsy results in reclassiﬁcation of cancer risk when compared with transrectal
ultrasound (TRUS) guided biopsy.
Design, setting, and participants: A total of 107 reconstructed three-dimensional mod-
els of whole-mount radical prostatectomy specimens were used for computer simula-
tions. Systematic 12-core TRUS biopsy was compared with transperineal targeted
biopsies using between one and ﬁve cores. All biopsy strategies incorporated operator
and needle deﬂection error. A target was deﬁned as any lesion 0.2 ml. A false-positive
magnetic resonance imaging identiﬁcation rate of 34% was applied.
Outcome measurements and statistical analysis: Sensitivity was calculated for the
detection of all cancer and clinically signiﬁcant disease. Cases were designated as high
risk based on achieving 6 mm cancer length and/or 50% positive cores. Statistical
signiﬁcance (p values) was calculated using both a paired Kolmogorov-Smirnov test and
the t test.
Results and limitations: When applying a widely used biopsy criteria to designate
risk, 12-core TRUS biopsy classiﬁed only 24% (20 of 85) of clinically signiﬁcant cases
as high risk, compared with 74% (63 of 85) of cases using 4 targeted cores. The
targeted strategy reported a signiﬁcantly higher proportion of positive cores (44% vs
11%; p < 0.0001) and a signiﬁcantly greater mean maximum cancer core length
(7.8 mm vs 4.3 mm; p < 0.0001) when compared with 12-core TRUS biopsy. Com-
puter simulations may not reﬂect the sources of errors encountered in clinical
practice. To mitigate this we incorporated all known major sources of error to
maximise clinical relevance.
Conclusions: Image-targeted biopsy results in an increase in risk attribution if tradi-
tional criteria, based on cancer core length and the proportion of positive cores, are
applied. Targeted biopsy strategies will require new risk stratiﬁcation models that
account for the increased likelihood of sampling the tumour.
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The current diagnostic pathway in prostate cancer relies on
the transrectal ultrasound (TRUS) guided prostate biopsy
test, applied after a man presents with an elevated serum
prostate-specific antigen. The random and systematic
errors that occur when this test is conducted blind to the
location of a cancer have been widely discussed [1–3].
State-of-the-art imaging such as multiparametric mag-
netic resonance imaging (mpMRI) [4] or novel ultrasound
(US) techniques [5] could overcome these errors by
providing information on the location and size of suspicious
lesions, thus allowing such lesions to be targeted.
Biopsy data are commonly used to determine cancer risk.
A targeted approach to lesions found on imaging may have
an impact on the risk attributed to a particular man.
Features widely used to indicate high risk include Gleason
score 7, as well as parameters to indicate the extent of
cancer such as maximum cancer core length (MCCL),
maximum percentage cancer, and the number of positive
biopsies [6]. However, if a tumour is exposed to a greater
sampling density than the rest of the prostate, it is likely
that the proportion of cores that are positive and the MCCL
will be greater compared with a TRUS biopsy. In addition,
higher Gleason patterns, if truly present, are more likely to
be sampled.
The aims of this studywere to establish whether, and the
extent to which, the phenomenon of risk escalation occurs
in men who undergo targeted biopsy, by means of a
computer simulation.
2. Materials and methods
From 1999 to 2001, 107 consecutive radical prostatectomywhole-mount
specimens that underwent 5-mm step sectioning according to the
Stanford protocol were analysed [7]. A single histopathologist contoured
all cancer foci by hand on each pathology slide. For each slice, the prostate
capsule and tumour contours were scanned and digitised using a ﬂatbed
scanner. A three-dimensional (3D) computermodel/image reconstruction
[(Fig._1)TD$FIG]
Fig. 1 – All-cancer sensitivity of biopsywas produced for each gland using custom-written computer software.
The scanned two-dimensional cross sections were ﬁrst aligned. Image
registration and a shape-based interpolation method matched the
adjacent gland slices to the chosen midgland reference slice [8–11]. A
data-speciﬁc correction factor was applied to estimate, and thereafter
reverse, the ﬁxation-related tissue shrinkage effect [11]. This correction
factor, calculated frommeasurements obtained before and after formalin
ﬁxation, was 1.10 (equivalent to a 33% increase in volume), assumed to be
isotropic, and applied to all specimens. The detailed methodology for this
3D reconstruction was previously described [12,13].
A false-positive rate for prostate mpMRI was incorporated. This was
based on a study recently published [14], in which image-targeted
biopsies were performed in 182 men with a lesion suspicious for
prostate cancer on mpMRI. MRI false positives are the result of an MRI
signal that is incorrect, a targeting miss, or a tissue capture failure. The
study demonstrated a 34% mpMRI false-positive rate. Applying this rate
to our simulation resulted in a total of 141 prostates for biopsy.
A false-negative rate for prostate mpMRI was not incorporated
because men with no lesion on mpMRI have no target for biopsy and
therefore revert to the standard of care, the TRUS biopsy.
It was previously demonstrated that lesions 0.2 ml in volume on
mpMRI can be detected with 77% sensitivity and 91% speciﬁcity [15];
therefore, we deﬁned a target as any lesion 0.2 ml.
2.1. Simulated biopsy
For each prostate model, 500 simulations of each biopsy strategy were
performed. The biopsy strategies included a 12-core TRUS biopsy and
transperineal targeted biopsies. In practice the number of image-
targeted cores taken depends on the clinical context and the operator
performing the biopsy. Therefore, each simulated transperineal targeted
scheme was repeated ﬁve times per prostate model, with the number of
targeted cores deployed ranging from one in the ﬁrst series to ﬁve in
the ﬁfth.
Errors were incorporated for all simulations to reﬂect registration (or
operator) deﬁciencies and needle deﬂection. In clinical practice, the total
targeting error equates to the sum of these two errors [16]. All biopsy
strategies were performed with a range of applied error, from 1 mm to
10 mm (Fig. 1); however, to ensure the results generated were
comparable, we set our total targeting error at 5 mm. This error was
calculated using (1) a needle deﬂection error with standard deviation
(SD) of 3 mm in any direction (measured at the midpoint of the effectivesimulations with increasing error.
[(Fig._3)TD$FIG]
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registration error with an SD of 3 mm (Fig. 2), which represents the
misalignment betweenMRI and TRUS images (ie, US-MRI registration error)
[17–19]. The set total variance of the error (25 mm2) was larger than the
additive variance (9 + 9 mm2). All errors were assumed to have zero-mean
normally distributed components in the three orthogonal directions.
2.2. Twelve-core transrectal ultrasound biopsy
For us to approximate the variability in the probe and needle trajectory
during TRUS biopsies,we estimated the anatomic position andorientation[(Fig._2)TD$FIG]
Fig. 2 – Simulated 12-core transrectal ultrasound biopsy. Correct
anatomic position and orientation estimated using T2-weighted
magnetic resonance imaging (1.5 T). Three-dimensional coordinates
taken from the centre of the anus and gland, and aligned with the base-
apex axis. Coordinates were used to approximate the variability in the
probe/needle insertion location and trajectory during simulated
biopsies. Simulated needle insertions were automatically calculated by
computer software, so the conduct of the biopsies was fully blinded to
the pathology.
Fig. 3 – Simulated targeted biopsy. Using a 5-mm brachytherapy
template, visible urethra was aligned to the D 2.0 grid coordinate on
midgland transverse view. Planned positions of the targeted cores
(1–5) were optimised so that the total cancer core length obtained was
maximised.of the prostate gland relative to the rectumusing T2-weightedMRI (1.5 T)
sequences of patients with prostate cancer. Three-dimensional coordi-
nates were taken from the centre of the anus and gland, and aligned with
the base-apex axis. This information allowed simulated needle insertions
tobeperformedautomaticallyby the computer software, so the conductof
the biopsies was fully blinded to the pathology, as would occur in clinical
practice (Fig. 2).
2.3. Transperineal targeted biopsy
Using a 5-mm brachytherapy template, the visible urethra was aligned
to the D 2.0 grid coordinate on a midgland transverse view (Fig. 3). The
planned positions of the targeted cores were optimised based on a
method developed in our research group; by aiming for the deepest part
of the lesion, the total cancer core length obtained was maximised.
2.4. Analyses
The MCCL and percentage of positive cores were evaluated for each
biopsy strategy. In our institution, three to four image-directed targeted
cores are typically taken per lesion. We have therefore focussed our
results to compare 12-core TRUS biopsy with the 3-core and 4-core
targeted biopsy strategies. Cases were designated as low or high risk
according to criteria detailed in Table 1.Table 1 – Simulation biopsy risk stratification criteria
Risk Histopathology criteria
High  6 mm maximum cancer core length
 50% positive cores
Low  <6 mm maximum cancer core length
 <50% positive cores
Table 2 – Baseline characteristics for prostate cases used in the
simulation
Characteristic, median
(mean, SD, range)
Value
Age, yr 62 (61.1, 6.4, 44–74)
PSA concentration, ng/ml 8.5 (9.7, 5.9, 0.8–36.2)
Gleason score, % (n)
6 57 (61)
7 35 (37)
8 8 (9)
Pathologic stage, % (n)
pT2a 7.5 (8)
pT2b 2 (2)
pT2c 49.5 (53)
pT3a 33.6 (36)
pT3b 5.6 (6)
pT4 2 (2)
Risk groups, NCCN classiﬁcation, % (n)
Low 5.6 (6)
Intermediate 47.7 (51)
High 46.7 (50)
Prostate volume, ml,
median (range)
50.2 (26.8–127.7)
No. of lesions
Anterior 415
Posterior 250
Full cohort
0.2 ml 149
0.5 ml 97
Low to intermediate risk
0.2 ml 68
0.5 ml 43
Lesions per prostate,
median (range)
5 (1–21)
Lesion volumes, ml, median (mean, SD, range)
All (n = 665) 0.031 (0.374, 1.110, 0.001–13.242)
Index (n = 107) 1.215 (1.895, 2.176, 0.015–13.242)
Nonindex (n = 558) 0.019 (0.082, 0.343, 0.001–1.842)
NCCN = National Comprehensive Cancer Network; PSA = prostate-speciﬁc
antigen; SD = standard deviation.
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Sensitivity was calculated for each biopsy strategy for the detection of all
cancer and clinically signiﬁcant disease (lesion size 0.5 ml and/or
Gleason grade 7). The impact of increasing the error was evaluated
(Fig. 1), as well as the proportion of detected cases that were attributed a
high-risk status (based on biopsy parameters) by each biopsy strategy
(Table 1). Statistical signiﬁcance (p value) was calculated using the
Student t test and a paired Kolmogorov-Smirnov test [20] (signiﬁcance
level a = 0.05) because the MCCL and percentage of positive cores have a
skewed distribution.
3. Results
Table 2 shows the baseline characteristics of prostate cancer
cases used in the simulation. Setting the total targeted error
at 5 mm, the sensitivity for all cancer detection was 0.46,
0.62, and 0.68 for the 12-core TRUS, 3-core, and 4-core
targeted biopsy strategies, respectively (Fig. 1). The 12-core
TRUS biopsy detected 91% (77 of 85) of clinically significant
cancers compared with 98% (83 of 85) and 99% (84 of 85)
detected using three or four targeted cores, respectively
(Fig. 4).
The targeted biopsies reported a significantly higher
proportion of positive cores ( p < 0.0001) and significantly
greater MCCLs ( p < 0.0001) (Table 3). When all cases with
cancer were considered, the mean MCCL was 2.7 mm,
4.6 mm, and 5.1 mm, and the proportion of positive cores
was 7%, 29%, and 28% for the 12-core TRUS biopsy, 3-core
targeted, and 4-core targeted biopsies, respectively. When
only considering cases that were clinically significant on
whole-mount histology, mean MCCL was 4.3 mm, 7.2 mm,
and 7.8 mm ( p < 0.0001), and the proportion of positive
cores was 11%, 45%, and 44% for the 12-core TRUS biopsy,
3-core targeted, and 4-core targeted schemes, respectively
( p < 0.0001).
[(Fig._4)TD$FIG]
Fig. 4 – Detection of all cancer, and clinically significant disease, using 12-core transrectal ultrasound (TRUS) biopsy and a 3- or 4-core targeted strategy.
CCL = cancer core length.
Table 3 – Proportion of positive cores and maximum cancer core lengths for transrectal ultrasound biopsy and three- or four-core targeted
biopsy*
Maximum cancer core length, mm Positive cores, %
Mean  SD Median 90th percentile Mean  SD Median 90th percentile
All data
TRUS 12 core 2.7  2.9 1.9 7.4 7.1  7.2 5.7 16.9
Targeted 3 core 4.6  3.9 4.3 10.2 29.3  24.1 30.9 63.7
Targeted 4 core 5.1  4.2 4.9 11.0 28.2  23.3 29.3 63.1
High risk (index volume 0.5 or Gleason7)
TRUS 12 core 4.3  2.7 3.9 8.2 11.0  6.7 10.1 21.5
Targeted 3 core 7.2  2.8 6.7 11.3 45.0  16.9 42.7 69.9
Targeted 4 core 7.8  2.9 7.4 11.9 43.5  16.3 41.0 68.0
Low risk (index volume <0.5 and Gleason <7)
TRUS 12 core 0.3  0.5 0.0 1.0 1.0  1.7 0.0 3.6
Targeted 3 core 0.7  1.1 0.0 2.7 5.4  9.0 0.0 20.2
Targeted 4 core 0.8  1.3 0.0 3.2 5.1  8.5 0.0 17.6
SD = standard deviation; TRUS = transrectal ultrasound.
* For all cancer, clinically signiﬁcant disease, and clinically insigniﬁcant disease.
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MCCL and/or 50% positive cores) (Table 1), the 12-core
TRUS biopsy correctly attributed a high-risk classification to
24% (20 of 85) clinically significant cases. This compared
with 66% (56 of 85) using the three-core targeted technique
and 74% (63 of 85) using the four-core targeted scheme
(Fig. 4).
We also evaluated how disease burden would be
represented by targeted and TRUS biopsy strategies in
those cases that were defined as clinically insignificant
(Gleason < 7 and/or lesion size <0.5 ml). All insignificant
lesions were attributed a low-risk classification when
applying our biopsy risk stratification criteria. However,
the targeted biopsy strategies demonstrated a higher
disease burden, with mean MCCL of 0.3 mm, 0.7 mm, and
0.8 mm, and the proportion of positive cores 1%, 5%, and 5%
for the 12-core TRUS biopsy, 3-core, and 4-core targeted
strategy, respectively (Table 3).
4. Discussion
Our simulation has shown that image-directed biopsy
introduces a systematic increase in risk attribution if risk
models derived from conventional TRUS biopsy are applied.
This agrees with clinical intuition because currently applied
risk stratification schemes are not optimised for men who
have a lesion defined on imaging who undergo tumour-
targeted biopsies.
4.1. Limitations
Before we consider the clinical implications of our results, it
is important to recognise certain limitations associatedwith
our method. First, the analysis of Gleason grade is limited in
the current study. We defined clinically significant disease
as Gleason 7 and/or volume 0.5 ml but were unable to
study the dominance of Gleason pattern 4 in more detail
because areas of patternwithin a lesion were not accurately
mapped.Second, the use of computer simulations may not reflect
true clinical practice. To mitigate for this we incorporated
errors to reflect operator/registration deficiencies and
needle deflection. In practice, there are three ways in
which targeted biopsies can be carried out: US-MRI fusion
or registration using overlay software, cognitive registra-
tion using TRUS guidance in which the operator effectively
eyeballs where the lesion may be as in our recent report,
and in-bore MRI targeting. US-MRI fusion registration, and
the associated error, has been widely researched [17–19].
Because fusion software is being used increasingly in
clinical practice, we specifically used this error to ensure our
results were reproducible and applicable. We acknowledge
that cognitive targetingwith TRUSwould involve applying a
much greater—but currently unquantifiable—error. The
accuracy of in-bore MRI-guided targeting is also uncertain,
but we would expect the error to be comparable or perhaps
even lower than using TRUS-MRI fusion, especially if a
robot-driven needle placement is used.
Third, TRUS biopsy and a transperineal-targeted strategy
differ with respect to needle orientation. This could affect
MCCL depending on lesion position and shape. Having said
this, there are both ethical and technical limitations to
exploring this phenomenon in vivo because there are limits
to the number of needle deployments thatmenwill tolerate,
and it would be impossible to subject men to repeated
testing. Blinding is also difficult due to needle tracking, as is
the elimination of the bias associated with order effects.
It is possible to biopsy radical prostatectomy specimens
prior to formalin fixation and whole-mount slicing, which
may help correct the deficiency in Gleason grade analysis.
However, such experiments are subject to various errors
that mean differences with the in vivo clinical procedure
will still exist. For example, coregistration of biopsy against
the processed specimen has numerous methodological
problems that include orientation error, gland shrinkage
and distortion, tissue loss through trimming, and difficulty
with standardising distance measurements in the direction
of the needle axis.
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opportunity to estimate the effect on risk stratification that
we can expect if we adopt an image-directed biopsy
strategy versus one that is not informed by location.
4.2. Clinical implications
The recent growth of interest in and accessibility to mpMRI
and novel US techniques as a means of localising prostate
cancer has led to image-directed targeted biopsy sampling
strategies being increasingly adopted [4,5]. A recent
systematic review of image-guided biopsy versus biopsy
blind to location suggests the superiority of the former [4].
In one of the largest studies included within the review,
Haffner and colleagues found that image-directed biopsies
were associated with a longer MCCL compared with
systematic biopsies, with values of 5.6 mm and 4.7 mm,
respectively. It was also reported that the image-targeted
biopsies were associated with a 16% greater detection of
Gleason grade 4/5 than systematic biopsies [21].
If the trend towards image-guided biopsy continues
unchecked, it is likely that we will witness a systematic
increase in risk attribution in the men subjected to biopsy if
the standard criteria for attributing risk are applied.
It is therefore likely that new risk prediction models
based on targeted biopsies will be required. As a start to
correct what could be regarded as an artefactual increase
in cancer risk derived from targeted biopsy, a risk
stratification system that is independent of the number
of positive cores could be considered. Some of these
systems have been validated and confer risk based on
Gleason grade and MCCL [13]. In a targeted biopsy that is
positive in >50% of the cores obtained from the target
region, it is likely that the MCCL is representative of the
maximum dimension of the tumour and may be used to
infer tumour volume. Recent studies have shown that our
threshold for clinical significance should be higher than
what was previously acceptable, with calls to raise the
volume threshold to 1.3 ml [22]. Incorporating the amount
of Gleason pattern 4 into risk models may also derive
considerable benefit [23]; such a parameter is likely to be
better represented by a targeted biopsy than a TRUS
biopsy [24].
One of the benefits of an image-directed strategy is that
it confers an upper ceiling of risk if the target is real and the
targeting accurate. Information on risk is more useful when
presented this way because patients can use this informa-
tion more readily in their choice of therapy. This compares
with TRUS-guided biopsy, which tends to give us informa-
tion on the lower limit of disease as a result of the random
sampling it uses. It is for this reason that men are upgraded
on review of radical prostatectomy histopathology or when
rebiopsied on active surveillance.
Our computer simulations are intended to explore a
concept, namely that of deliberately oversampling a given
volume of tissue. We anticipate that more work using ex
vivo tissue sampled in a targeted manner will in particular
have some utility in exploring the distribution of Gleason
patterns when we target versus times when we do not.5. Conclusions
Our computer simulation showed an increase in MCCL and
the proportion of cores that were positive when an image-
directed biopsy was compared with a non–image-directed
biopsy. This could lead to inflation in risk attribution as a
consequence of deliberate oversampling of one part of the
prostate—in other words targeting. New risk stratification
models may be required for men who have pathology
derived from image-directed biopsy strategies.
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